Amylyx Overview

  • Founded
  • 2013
Founded
  • Status
  • Public
  • Employees
  • 110
Employees
  • Stock Symbol
  • AMLX
Stock Symbol
  • Share Price
  • $26.45
  • (As of Monday Closing)

Amylyx General Information

Description

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.

Contact Information

Website
www.amylyx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
  • 43 Thorndike Street
  • Cambridge, MA 02141
  • United States
+1 (617) 000-0000

Amylyx Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amylyx Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$26.45 $27.39 $16.00 - $33.41 $1.55B 56.5M 422K -$1.50

Amylyx Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
Revenue 0 0 0
EBITDA (68,153) (40,005) (12,616)
Net Income (68,179) (42,280) (13,716)
Total Assets 130,460 14,104 3,220
Total Debt 263 1,425 14,931
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amylyx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amylyx‘s full profile, request access.

Request a free trial

Amylyx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Amylyx‘s full profile, request access.

Request a free trial

Amylyx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyo
Drug Discovery
Cambridge, MA
110 As of 2021
00000
0.000 0000-00-00
00000000 00000

00000000

itation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehende
0000 000000000
Cambridge, MA
0 As of 0000
0000
0000000000 0000

0000000

rure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteu
0000 000000000
Cambridge, MA
0000 As of 0000
00.000
0000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amylyx Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aquinnah Venture Capital-Backed Cambridge, MA 0 0000 0000000000 0000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
0000000 Formerly VC-backed Boston, MA 0000 000000&0
000000000 Formerly VC-backed Copenhagen, Denmark 000 00000 000000000 00000
000000000 00000000 Venture Capital-Backed New York, NY 00 000.00 00000000 000.00
You’re viewing 5 of 9 competitors. Get the full list »

Amylyx Patents

  • 27

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Amylyx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210177867-A1 Compositions of bile acids and phenylbutyrate compounds Pending 16-Dec-2019 000000000
US-20210186990-A1 Methods and compositions for treating various disorders Pending 16-Dec-2019 000000000
US-10251896-B2 Compositions for improving cell viability and methods of use thereof Active 24-Mar-2013 0000000000 0
US-9872865-B2 Compositions for improving cell viability and methods of use thereof Active 24-Mar-2013 0000000000 0
US-20140288030-A1 Compositions for improving cell viability and methods of use thereof Granted 24-Mar-2013 A61K31/575
To view Amylyx’s complete patent history, request access »

Amylyx Executive Team (10)

Name Title Board Seat Contact Info
Joshua Cohen Chief Executive Officer & Board Member
Justin Klee Chief Executive Officer & Board Member
Debra Canner Global Head of Human Resources & Chief Human Resources Officer
Gina Mazzariello Chief Legal Officer & General Counsel
Kent Leslie Chief Scientific Officer & Global Head, Research & Development
You’re viewing 5 of 10 executive team members. Get the full list »

Amylyx Board Members (14)

Name Representing Role Since
Alan Walts Ph.D Self Board Observer 000 0000
Daphne Quimi Self Board Member 000 0000
Daphne Quimi Amylyx Board Member 000 0000
Felix von Coerper ALS Investment Fund Board Member 000 0000
George Milne Amylyx Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Amylyx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amylyx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Amylyx‘s full profile, request access.

Request a free trial